Momenta Pharmaceuticals (MNTA) 11.59 $MNTA
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:45PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) will use the antibodies acquired from AnaptysBio for developing a novel recombinant antibody targeting specific autoimmune disorders.
Momenta Pharmaceuticals reports exercise of option to purchase novel antibody programme from AnaptysBio
M2 - Tue Sep 09, 6:22AM CDT
Biotechnology company Momenta Pharmaceuticals (NasdaqGS:MNTA) revealed on Monday the exercise of its option to acquire a novel antibody programme from AnaptysBio for an option exercise fee.
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it has exercised its option to acquire novel antibodies generated by AnaptysBio, Inc., a privately-held therapeutic antibody company, as part of the previously announced agreement between the two companies.
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibody Program from AnaptysBio
PR Newswire - Mon Sep 08, 7:30AM CDT
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, has exercised its option to acquire a novel antibody program from AnaptysBio. Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg. The aforementioned option right was granted by AnaptysBio to Momenta under an agreement signed between the companies in December 2013.
Momenta-Sandoz's Generic Copaxone Accepted for Review by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 2:20PM CDT
Momenta Pharmaceuticals (MNTA) announced that the FDA has accepted Sandoz's abbreviated new drug application for generic Copaxone for review.
Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA
GlobeNewswire - Thu Aug 28, 10:43AM CDT
Momenta Pharmaceuticals (Nasdaq:MNTA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for a three-times-a-week generic COPAXONE(R) (glatiramer acetate injection, 40 mg/mL), submitted by Sandoz Inc., Momenta's development and commercialization partner for this product candidate.
Technical Roundup on Biotech Stocks -- Medivation, Ironwood Pharma, Momenta Pharma, Galectin Therapeutics, and PDL BioPharma
PR Newswire - Tue Aug 12, 7:50AM CDT
The trading session on Monday, August 11, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 700.04, up 0.01%, and the index has advanced 4.74% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Galectin Therapeutics Inc. (NASDAQ: GALT) and PDL BioPharma Inc. (NASDAQ: PDLI). Free research on these five companies can be accessed at:
Momenta Posts Narrower Q2 Loss, Revenues Up Y/Y, Shares Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:50AM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported second-quarter 2014 net loss per share of 51 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents but narrower than the year-ago loss of 57 cents.
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2014.
Momenta Pharmaceuticals to Webcast Presentation at the Canaccord Genuity Growth Conference
GlobeNewswire - Wed Jul 30, 3:14PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Canaccord Genuity Growth Conference will be webcast on Thursday, August 14 at 4:00 p.m. ET.
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2014 before the U.S. financial markets open on Thursday, July 31, 2014.
Teva's Contraceptive Gets Positive CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:00PM CDT
Teva Pharmaceutical Industries Ltd.'s (TEVA) extended-regimen oral contraceptive, Seasonique got a positive recommendation from theCommittee for Medicinal Products for Human Use.
Buy, Sell, or Hold This Generic Pharma Titan?
Chuck Saletta, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
Teva Pharmaceuticals is the world's largest generic-drug maker. Somewhat ironically for a company that specializes in generics, its business is struggling at the moment as its own blockbuster patent-protected drug, Copaxone, just lost its patent...
Earnings Estimates Moving Higher for Momenta Pharmaceuticals (MNTA): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 7:42AM CDT
Momenta Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Battle of the Biotech Bands - A Great Time for a Great Cause
PR Newswire - Thu Jun 12, 1:45PM CDT
BioBridges, a leading clinical contract consulting company, is so proud to have joined the sponsorship of the second annual Battle of the Biotech Bands. BoBB is a fun, community-driven, networking event with fundraising efforts supporting the charitable foundation affiliated with each biotech band.
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:55AM CDT
Momenta Pharma saw a big move last session, as the company’s shares fell by nearly 17% on the day.
Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 31, 6:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Legal Woes Piling Up for Teva Pharmaceutical Industries Ltd
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 3:12PM CDT
Editor's Note: Shortly after this article's publication, news outlets reported that the Supreme Court has agreed to a hearing on generic Copaxone. The article has been adjusted to reflect the updated information. Over the past week Teva 's ...
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:45PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) will use the antibodies acquired from AnaptysBio for developing a novel recombinant antibody targeting specific autoimmune disorders.
Momenta Pharmaceuticals reports exercise of option to purchase novel antibody programme from AnaptysBio
M2 - Tue Sep 09, 6:22AM CDT
Biotechnology company Momenta Pharmaceuticals (NasdaqGS:MNTA) revealed on Monday the exercise of its option to acquire a novel antibody programme from AnaptysBio for an option exercise fee.
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it has exercised its option to acquire novel antibodies generated by AnaptysBio, Inc., a privately-held therapeutic antibody company, as part of the previously announced agreement between the two companies.
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibody Program from AnaptysBio
PR Newswire - Mon Sep 08, 7:30AM CDT
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, has exercised its option to acquire a novel antibody program from AnaptysBio. Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg. The aforementioned option right was granted by AnaptysBio to Momenta under an agreement signed between the companies in December 2013.
Momenta-Sandoz's Generic Copaxone Accepted for Review by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 2:20PM CDT
Momenta Pharmaceuticals (MNTA) announced that the FDA has accepted Sandoz's abbreviated new drug application for generic Copaxone for review.
Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA
GlobeNewswire - Thu Aug 28, 10:43AM CDT
Momenta Pharmaceuticals (Nasdaq:MNTA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for a three-times-a-week generic COPAXONE(R) (glatiramer acetate injection, 40 mg/mL), submitted by Sandoz Inc., Momenta's development and commercialization partner for this product candidate.
Technical Roundup on Biotech Stocks -- Medivation, Ironwood Pharma, Momenta Pharma, Galectin Therapeutics, and PDL BioPharma
PR Newswire - Tue Aug 12, 7:50AM CDT
The trading session on Monday, August 11, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 700.04, up 0.01%, and the index has advanced 4.74% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Galectin Therapeutics Inc. (NASDAQ: GALT) and PDL BioPharma Inc. (NASDAQ: PDLI). Free research on these five companies can be accessed at:
Momenta Posts Narrower Q2 Loss, Revenues Up Y/Y, Shares Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:50AM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported second-quarter 2014 net loss per share of 51 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents but narrower than the year-ago loss of 57 cents.
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2014.
Momenta Pharmaceuticals to Webcast Presentation at the Canaccord Genuity Growth Conference
GlobeNewswire - Wed Jul 30, 3:14PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Canaccord Genuity Growth Conference will be webcast on Thursday, August 14 at 4:00 p.m. ET.
World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2014 before the U.S. financial markets open on Thursday, July 31, 2014.
Teva's Contraceptive Gets Positive CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:00PM CDT
Teva Pharmaceutical Industries Ltd.'s (TEVA) extended-regimen oral contraceptive, Seasonique got a positive recommendation from theCommittee for Medicinal Products for Human Use.
Buy, Sell, or Hold This Generic Pharma Titan?
Chuck Saletta, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
Teva Pharmaceuticals is the world's largest generic-drug maker. Somewhat ironically for a company that specializes in generics, its business is struggling at the moment as its own blockbuster patent-protected drug, Copaxone, just lost its patent...
Earnings Estimates Moving Higher for Momenta Pharmaceuticals (MNTA): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 7:42AM CDT
Momenta Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Battle of the Biotech Bands - A Great Time for a Great Cause
PR Newswire - Thu Jun 12, 1:45PM CDT
BioBridges, a leading clinical contract consulting company, is so proud to have joined the sponsorship of the second annual Battle of the Biotech Bands. BoBB is a fun, community-driven, networking event with fundraising efforts supporting the charitable foundation affiliated with each biotech band.
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:55AM CDT
Momenta Pharma saw a big move last session, as the company’s shares fell by nearly 17% on the day.
Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 31, 6:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Legal Woes Piling Up for Teva Pharmaceutical Industries Ltd
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 3:12PM CDT
Editor's Note: Shortly after this article's publication, news outlets reported that the Supreme Court has agreed to a hearing on generic Copaxone. The article has been adjusted to reflect the updated information. Over the past week Teva 's ...
